Delstrigo - Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
From Products List - D
DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2018.
-
Most popular related searches
Products Details
INDICATIONS AND USAGE
DELSTRIGO is a three-drug combination of doravirine (a non-nucleoside reverse transcriptase inhibitor [NNRTI]). lamivudine, and tenofovir disoproxil fumarate (both nucleoside analogue reverse transcriptase inhibitors) and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg:
- with no antiretroviral treatment history. OR
- to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per ml_) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO. (1)
Customer reviews
No reviews were found for Delstrigo - Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets. Be the first to review!